Safety, Efficacy, and Changes in Traditional and Novel Biomarkers of Kidney Function in Patients With Hepatitis C and Advanced Chronic Kidney Disease Treated With Abbvie Viekira Pak Regimen
Phase of Trial: Phase IV
Latest Information Update: 05 Jun 2017
At a glance
- Drugs Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C; Renal failure
- Focus Therapeutic Use
- 26 May 2017 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 26 May 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 26 May 2017 Status changed from not yet recruiting to recruiting.